MEN-ENDO: Menstrual Stem Cells in Endometriosis
Study of the Role of Menstrual Blood-derived Stem Cells and the Immune Environment in Endometriosis
Endometriosis is a chronic inflammatory condition characterized by the presence of endometrium-like tissue outside the uterine cavity. It is estimated to affect approximately 10% of women of reproductive age and it is associated with chronic pelvic pain and infertility, among other symptoms.
Endometriosis involves complex changes in the body's cells and immune response. For this reason, the goal of this observational study is to characterize the functional, molecular, and immunological alterations in menstrual blood-derived stem cells (MenSCs) and differentiated decidual stromal cells in women with endometriosis; to validate these findings in endometrial tissue and endometriomas; and to establish their correlation with clinical parameters, with the aim of identifying key pathogenic mechanisms and potential therapeutic targets.
The main questions it aims to answer are:
- Are there functional and molecular changes in MenSCs from patients with endometriosis compared to healthy volunteers?
- Are there any variations in the immune properties of MenSCs throughout the menstrual bleeding period in patients with endometriosis compared to healthy volunteers?
- Are these changes also present in endometrial tissue and endometrioma samples?
- Can these changes be correlated with clinical parameters in patients with endometriosis?
- Can MenSCs serve as a potential therapeutic target for endometriosis?
Some participants will be asked to provide menstrual blood on a single day, while others will provide samples during the first five days of menstruation. Additionally, all participants will answer questionnaires about their diet, physical activity, stress, and pain levels. Therefore, the study does not involve the evaluation of a specific intervention on the participants.
The results will enable the identification of key altered mechanisms and potential therapeutic targets, thereby contributing to the development of more effective strategies for the diagnosis and treatment of the disease.
調査の概要
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Dr. Francisco Algaba-Chueca
- 電話番号:+34623966066
- メール:francisco.algaba@urv.cat
研究連絡先のバックアップ
- 名前:Dr. Victoria Linares-Vidal
- 電話番号:+34977759374
- メール:mvictoria.linares@urv.cat
研究場所
-
-
Tarragona
-
Reus、Tarragona、スペイン、43201
- 積極的、募集していない
- Universitat Rovira i Virgili. Facultat de Medicina i Ciències de la Salut
-
Tarragona、Tarragona、スペイン、43005
- 募集
- Hospital Universitari Joan XXIII
-
コンタクト:
- Dr. Joana Galera Ortega
- 電話番号:+34977295800
- メール:jgalera.hj23.ics@gencat.cat
-
コンタクト:
- Dr. Albert Guarque Rus
- 電話番号:+34977295835
- メール:aguarque.hj23.ics@gencat.cat
-
-
参加基準
適格基準
就学可能な年齢
- 大人
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
Our study population consists of 40 women aged between 18 and 45, 20 of whom have been diagnosed with endometriosis and 20 of whom are healthy volunteers. Participants will be recruited from the Department of Gynecology and Obstetrics at the Hospital Universitari Joan XXIII in Tarragona (Spain) during routine gynecological check-ups. Healthy volunteers will be selected through individual matching with participants in the study group, considering relevant demographic and clinical variables such as age and ethnic group.
In addition, a sub-cohort of 10 women (5 per study group) will be selected from the main cohort to study in greater detail the intra-menstrual variations in the immunomodulatory properties of MenSCs. This sub-cohort will include participants who agree to provide menstrual blood samples from days 1 to 5 (both inclusive) to analyze dynamic changes in the cells obtained, while maintaining the same general inclusion and exclusion criteria as in the main study.
説明
Inclusion Criteria:
- 18-45 years.
- Endometriosis group: Women with clinical and/or ecographical diagnostic of endometriosis.
- Control group: Women with the endometriosis diagnosis.
Exclusion Criteria:
- <18 years or >45 years.
- Pregnancy or lactation.
- Diagnosis of prior chronic pelvic inflammatory or autoimmune disease.
- History of active gynecological cancer.
- Positive for human immunodeficiency virus (HIV) or human papillomavirus (HPV).
- Hormonal therapy use in the previous 3 months.
- Use of immunosuppressants or corticosteroids in the previous 3 months.
- Systemic antibiotics use in the previous 3 months.
- Insufficient menstrual flow to allow the MenSCs isolation.
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Endometriosis
|
Menstrual-blood derived stem cells will be isolated from the menstrual blood of patients with endometriosis and healthy volunteers to be characterized in vitro.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
MenSCs proliferation rate
時間枠:Through study completion (average of 3 years)
|
Evaluation of the expansion capacity of MenSCs from endometriosis patients vs. healthy controls using the MTT assay.
|
Through study completion (average of 3 years)
|
|
Phenotypic characterization of MenSCs
時間枠:Through study completion (average of 3 years).
|
Evaluation of surface marker expression using flow cytometry to determine the phenotype of MenSCs from endometriosis patients and healthy controls.
|
Through study completion (average of 3 years).
|
|
MenSC chemotaxis
時間枠:Through study completion (average of 3 years)
|
Assessment of the number of T-lymphocytes and monocytes capable of migrating through a transwell membrane under the stimuli of conditioned media from MenSCs obtained from endometriosis patients and healthy controls.
|
Through study completion (average of 3 years)
|
|
MenSC invasion capacity
時間枠:Through study completion (average of 3 years)
|
Assessment of the number of MenSCs from endometriosis patients vs. healthy controls capable of degrading a Matrigel on a transwell membrane and migrating toward a chemoattractant.
|
Through study completion (average of 3 years)
|
|
Multilineage capacity of MenSCs
時間枠:Through study completion (average of 3 years)
|
The differentiation potential of MenSCs from endometriosis patients vs. healthy controls towards osteocytes, chondrocytes and adipocytes will be assessed by using specific media.
|
Through study completion (average of 3 years)
|
|
Decidualitzation response to progesterone of the decidual cells differentiated from MenSCs from endometriosis patients and healthy volunteers
時間枠:Through study completion (average of 3 years).
|
MenSCs will be cultured in presence of 8-Br-cAMP during 14 days, and the assessment of morphology and expression of decidual markers will be performed by RT-qPCR and ELISA assay.
|
Through study completion (average of 3 years).
|
|
Apoptosis resistance assessment of the decidual cells differentiated from MenSCs from endometriosis patients and healthy volunteers
時間枠:Through study completion (average of 3 years).
|
Apoptosis resistance will be evaluated by Annexin V/PI flow cytometry following induction by TNFα.
Additionally, the expression of key apoptotic mediators will be quantified using RT-qPCR and Western blot.
|
Through study completion (average of 3 years).
|
|
Cytokine profile of the secretome of MenSCs from endometriosis patients and healthy volunteers and their differentiated decidual cells.
時間枠:Through study completion (average of 3 years).
|
The conditioned media will be assessed to determine the cytokines secreted using an ELISA assay.
|
Through study completion (average of 3 years).
|
|
Cytokine profile of the endometrial and endometrioma tissues
時間枠:Through study completion (average of 3 years).
|
The levels of cytokines in the conditioned media from cultured explants will be assessed by ELISA assay.
|
Through study completion (average of 3 years).
|
|
Cytokine profile of the secretome of immune cells populations
時間枠:Through study completion (average of 3 years)
|
The levels of cytokines in the conditioned media from lymphocytes and macrophages will be assessed by ELISA assay.
|
Through study completion (average of 3 years)
|
|
Cytokine profile of the peripheral blood plasma
時間枠:Through study completion (average of 3 years)
|
The levels of cytokines in peripheral blood plasma from endometriosis patients and healthy volunteers will be determined by ELISA assay.
|
Through study completion (average of 3 years)
|
|
Gene expression profile of MenSCs from endometriosis patients and healthy volunteers and their differentiated decidual cells
時間枠:Through study completion (average of 3 years)
|
Total RNA expression of targeted genes will be analyzed by RT-qPCR.
|
Through study completion (average of 3 years)
|
|
Gene expression profile of the endometrial and endometrioma tissues
時間枠:Through study completion (average of 3 years).
|
Total RNA expression of targeted genes will be analyzed by RT-qPCR.
|
Through study completion (average of 3 years).
|
|
Gene expression profile of the immune cells populations
時間枠:Through study completion (average of 3 years)
|
Total RNA expression of targeted genes will be analyzed by RT-qPCR.
|
Through study completion (average of 3 years)
|
|
Protein expression of MenSCs from endometriosis patients and healthy volunteers and their differentiated decidual cells
時間枠:Through study completion (average of 3 years)
|
Analysis of the protein expression profile via Western Blot.
|
Through study completion (average of 3 years)
|
|
Protein expression in endometrial and endometrioma tissues
時間枠:Through study completion (average of 3 years)
|
Analysis of the protein expression profile via Western Blot.
|
Through study completion (average of 3 years)
|
|
Protein expression in immune cells populations
時間枠:Through study completion (average of 3 years)
|
Analysis of the protein expression profile via Western Blot.
|
Through study completion (average of 3 years)
|
|
T cells activation
時間枠:Through study completion (average of 3 years)
|
T cells will be exposed to conditioned media from MenSCs from healthy volunteers and endometriosis patients.
Afterwards, the levels of IL-10 and IFNy will be determined by ELISA assay.
|
Through study completion (average of 3 years)
|
|
T cells proliferation rate
時間枠:Through study completion (average of 3 years)
|
T cells will be exposed to conditioned media from MenSCs from healthy volunteers and endometriosis patients.
Afterwards, their proliferative capacity will be assessed by MTT assay.
|
Through study completion (average of 3 years)
|
|
Cytokine secretion profile of macrophages
時間枠:Through study completion (average of 3 years)
|
The levels of cytokines in the supernatant of polarized macrophages after incubation with MenSC-derived conditioned media from endometriosis patients and healthy volunteers will be determined by ELISA assay.
|
Through study completion (average of 3 years)
|
|
Gene expression profile of macrophages
時間枠:Through study completion (average of 3 years)
|
Total RNA expression of targeted genes will be analyzed by RT-qPCR.
|
Through study completion (average of 3 years)
|
|
Protein expression of macrophages
時間枠:Through study completion (average of 3 years)
|
Analysis of the protein expression profile via Western Blot.
|
Through study completion (average of 3 years)
|
|
Phagocytic capacity of macrophages
時間枠:Through study completion (average of 3 years)
|
Assessment of the macrophages' ability to engulf fluorescently labeled apoptotic bodies from MenSCs via flux cytometry and fluorescence microscopy.
|
Through study completion (average of 3 years)
|
|
Angiogenic potential of macrophages conditioned media
時間枠:Through study completion (average of 3 years)
|
Evaluation of the ability of macrophage-derived conditioned media to induce tube formation (Matrigel) in Human Umbilical Vein Endothelial Cells (HUVECs).
|
Through study completion (average of 3 years)
|
|
Exploration of targeted interventions to reverse the pathological phenotype of MenSCs and macrophages derived from menstrual blood.
時間枠:Through study completion (average of 3 years).
|
Signaling pathways and genes involved in the altered phenotype will be blocked and silenced, respectively, to evaluate if these actions reverse the cellular response to the levels of the healthy volunteers' cells.
|
Through study completion (average of 3 years).
|
|
Correlation of cellular, tissue and molecular findings with patients' clinical parameters.
時間枠:Through study completion (average of 3 years).
|
The associations among the functional and immunological properties of MenSCs and macrophages, clinical parameters and dietary and behavioral habits will be stablished.
These clinical parameters include endometriosis stage, pain and fertility status, and the extent and localization of the endometriosis foci.
|
Through study completion (average of 3 years).
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- MEN-ENDO CEIm 308/2025
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。